<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b6585925-c3fb-4b61-808d-42ea232ca899"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use OPTISON safely and effectively. See full prescribing information for OPTISON.<br/>
      <br/>
      <br/>
      <br/>OPTISON (perflutren protein-type A microspheres) injectable suspension, for intravenous use<br/>
      <br/>Initial U.S. Approval: 1997</title>
   <effectiveTime value="20250514"/>
   <setId root="46bcf276-d423-408a-a410-f11383406a94"/>
   <versionNumber value="22"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="053046579"/>
            <name>GE Healthcare Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="515048908"/>
                        <name>GE Healthcare AS</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-2707" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="301119178"/>
                        <name>Octapharma Pharmazeutika Produktionsgesellschaft, m.b.H</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-2707" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="558833179"/>
                        <name>Octapharma AB</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-2707" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7561db00-e4f9-4db7-9cd8-2ac128e74f71"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250514"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0407-2707" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Optison<suffix>Perflutren Protein-Type A Microspheres</suffix>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Human Albumin Microspheres and Perflutren</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4460NBV53F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>N-ACETYL-DL-TRYPTOPHAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.12"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OBL58JN025" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CAPRYLIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="T8C6W1N6NW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HUMAN ALBUMIN MICROSPHERES</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="T8C6W1N6NW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HUMAN ALBUMIN MICROSPHERES</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.22"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CK0N3WH0SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PERFLUTREN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK0N3WH0SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PERFLUTREN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-2707-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102839" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 6: Drug/Biologic Combination" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="18" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-2707-18" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102839" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 6: Drug/Biologic Combination" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020899" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20020102"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>Clear lower layer and white upper layer</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="17d4ee0e-05a8-4850-910e-92ef7620cb7a"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: SERIOUS CARDIOPULMONARY REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Assess all patients for the presence of any condition that precludes OPTISON administration <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Always have resuscitation equipment and trained personnel readily available <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SERIOUS CARDIOPULMONARY REACTIONS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Assess all patients for the presence of any condition that precludes OPTISON administration (<linkHtml href="#S4">4</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">Always have resuscitation equipment and trained personnel readily available (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="10a9e39e-6328-4c10-be71-24b1376fbf6b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="80%" align="left" valign="bottom"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>5/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Recommended Dosage (<linkHtml href="#S2.1">2.1</linkHtml>)</td>
                                 <td>5/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Preparation Instructions (<linkHtml href="#S2.2">2.2</linkHtml>)</td>
                                 <td>5/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Administration Instructions (<linkHtml href="#S2.3">2.3</linkHtml>)</td>
                                 <td>5/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions, Transmissible Infectious Agents (5.5) - Removed</td>
                                 <td>5/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="774ba686-ce1c-445d-842f-428839857dcf"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">OPTISON is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>OPTISON is an ultrasound contrast agent indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders (<linkHtml href="#S1">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="b9ef1860-c02a-42c0-bd1a-ce0dce0987a5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Adults<list listType="unordered" styleCode="circle">
                                 <item>0.5 mL intravenously at a rate not exceeding 1 mL/s.</item>
                                 <item>If contrast enhancement is inadequate after the dose of 0.5 mL, additional doses of 0.5 mL may be repeated up to a total of 5 mL in a 10-minute period with a maximum total dose of 8.7 mL in any one patient study (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                              </list>
                           </item>
                           <item>Pediatric Patients <list listType="unordered" styleCode="circle">
                                 <item>28 kg or less: 0.2 mL diluted with 0.2 mL of 0.9% Sodium Chloride Injection.</item>
                                 <item>29 kg to 40 kg: 0.3 mL diluted with 0.3 mL of 0.9% Sodium Chloride Injection.</item>
                                 <item>41 kg or more: 0.4 mL diluted with 0.4 mL of 0.9% Sodium Chloride Injection.</item>
                                 <item>Administer intravenously at a rate not exceeding 0.05 mL/s.</item>
                                 <item>If contrast enhancement is inadequate after the initial dose, up to four additional doses of the same diluted volume may be repeated for further contrast enhancement as needed (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                              </list>
                           </item>
                           <item>Follow the OPTISON injection with a flush of 0.9% Sodium Chloride Injection or 5% Dextrose Injection (<linkHtml href="#S2.3">2.3</linkHtml>).</item>
                           <item>See full prescribing information for preparation instructions (<linkHtml href="#S2.2">2.2</linkHtml>). </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="6c74c97a-8aac-4d0a-8645-5179496a562e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Dosage</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="673bdce7-0291-463f-8e48-725cd9eac880"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                              <list>
                                 <item>The recommended dose in adults is 0.5 mL administered intravenously at a rate not exceeding 1 mL/s <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. </item>
                                 <item>If the contrast enhancement is inadequate after the dose of 0.5 mL, additional doses of 0.5 mL may be repeated for further contrast enhancement as needed. </item>
                                 <item>The maximum total dose is 5 mL in any 10-minute period.</item>
                                 <item>The maximum total dose is 8.7 mL in any one patient study.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="91ac1c60-d5d5-43ce-ac19-93f4c9313d25"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Pediatric Patients</content>
                                 </content>
                              </paragraph>
                              <list>
                                 <item>
                                    <content styleCode="xmChange">The recommended dose by body weight in pediatric patients is shown in Table 1. </content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Administer by intravenous injection at a rate not exceeding 0.05 mL/s <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. </content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">If the contrast enhancement is inadequate after the initial dose, up to four additional doses of the same diluted volume may be repeated for further contrast enhancement as needed.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">OPTISON must be diluted with 0.9% Sodium Chloride Injection to form a 1:1 dilution for pediatric administration <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                                    </content>
                                    <table width="65%" ID="table1">
                                       <caption>Table 1. Recommended Dose of OPTISON by Body Weight in Pediatric Patients </caption>
                                       <col width="25%" align="left" valign="middle"/>
                                       <col width="75%" align="left" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">Body Weight</content>
                                             </th>
                                             <th styleCode="Rrule">Dose</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">28 kg or less</content>
                                             </td>
                                             <td styleCode="Rrule">0.2 mL of OPTISON diluted with 0.2 mL of 0.9% Sodium Chloride Injection</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">29 kg to 40 kg</content>
                                             </td>
                                             <td styleCode="Rrule">0.3 mL of OPTISON diluted with 0.3 mL of 0.9% Sodium Chloride Injection </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">41 kg or more</content>
                                             </td>
                                             <td styleCode="Rrule">0.4 mL of OPTISON diluted with 0.4 mL of 0.9% Sodium Chloride Injection </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="8c94cf9a-5908-402d-8319-8e77def6234f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Preparation Instructions</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="804d4388-2129-4faa-a723-dcbc318949e5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Visually inspect the OPTISON vial. Do not use if the container has been damaged, the protective seal and/or rubber cap have been entered, or the upper white layer is absent (may indicate the microspheres have been damaged and may result in poor or no echo contrast).</item>
                                 <item>Invert the vial and gently rotate to resuspend the microspheres. This process will allow the product to come to room temperature (20°C to 25°C or 68°F to 77°F) before use.</item>
                                 <item>Inspect the vial for complete resuspension. Do not use if the suspension appears to be clear rather than opaque and milky-white.</item>
                                 <item>Vent the OPTISON vial with a sterile vent spike or with a sterile 18-gauge needle before withdrawing the OPTISON suspension into the injection syringe.</item>
                                 <item>
                              Do not inject air into the vial.</item>
                                 <item>Use the product within one minute of suspension. If one minute is exceeded, resuspend by inverting and gently rotating the syringe for no less than 10 seconds. Failure to adequately resuspend OPTISON may cause inadequate delivery of the microspheres and may result in inadequate contrast.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b8477621-b0ae-4b7f-8387-08e73ccb211a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Dilution for Pediatric Administration </content>
                                 </content>
                              </paragraph>
                              <list>
                                 <item>
                                    <content styleCode="xmChange">Invert the OPTISON vial and gently rotate to resuspend the microspheres.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Draw equal volumes of OPTISON and 0.9% Sodium Chloride Injection into the same syringe to form a 1:1 dilution.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Mix gently by holding the syringe horizontally between the palms and rolling it gently back and forth for at least 10 seconds.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">If not used within 10 minutes after dilution, discard the diluted product.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="0650b135-1062-4f84-879c-792d32a321e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>OPTISON is for intravenous use only and must not be administered by intra-arterial injection <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.  </item>
                           <item>Inspect visually for foreign particulate matter and discoloration prior to administration, whenever suspension and container permit. Do not inject if the suspension is not opaque and milky-white, or foreign particulate matter is present.</item>
                           <item>For adults, inject through a 20-gauge or larger angiocatheter into a peripheral vein at a rate not exceeding 1 mL/s as a faster rate may reduce performance of the OPTISON microspheres<content styleCode="italics">.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">For pediatric patients, inject through a 24-gauge or larger angiocatheter into a peripheral vein at a rate not exceeding 0.05 mL/s as a faster rate may reduce performance of the OPTISON microspheres<content styleCode="italics">.</content>
                              </content>
                           </item>
                           <item>Suggested methods of administration include: a short extension tubing, heparin lock, or intravenous line, all with a 3-way stopcock.</item>
                           <item>
                              <content styleCode="bold">Do not aspirate</content> blood back into the OPTISON-containing syringe before administration; this may promote the formation of a blood clot within the syringe.</item>
                           <item>For short extension tubing or heparin lock, fill one syringe with 10 mL of 0.9% Sodium Chloride Injection for adults or 5 mL of 0.9% Sodium Chloride Injection for pediatric patients and flush the line for patency before and after the injection of OPTISON.</item>
                           <item>For a continuous intravenous line, open an intravenous line with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to maintain vascular patency. Flush the line in its entirety immediately after injection of OPTISON.</item>
                           <item>Each vial is for single-patient use. Discard unused portion.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d921e281-2a75-474c-b9d6-345cc615efe7"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injectable suspension: 5-8×10<sup>8</sup>/mL protein-type A microspheres, 10 mg/mL albumin human, and 0.22 ± 0.11 mg/mL perflutren as a clear liquid lower layer, a white liquid upper layer, and a headspace filled with perflutren gas in 3 mL single-patient use vial; after resuspension, OPTISON is a sterile, homogeneous, opaque, and milky-white injectable suspension. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injectable suspension: 5-8 ×10<sup>8</sup>/mL protein-type A microspheres, 10 mg/mL albumin human, and 0.22 ± 0.11 mg/mL perflutren in 3 mL single-patient use vials (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4517a4ac-23e7-418f-a136-8f9a5a799209"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph>							OPTISON is contraindicated in patients with known or suspected hypersensitivity to perflutren or albumin <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. 						</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known or suspected hypersensitivity to perflutren or albumin (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="147119e7-a6e9-46dd-bfa6-674fa967dcd8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity Reactions: Serious anaphylactic reactions have been observed. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to OPTISON administration and monitor all patients for hypersensitivity reactions (<linkHtml href="#S5.2">5.2</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="185e6489-8757-4f4b-b9ce-8e4e817e84b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Serious Cardiopulmonary Reactions</title>
                     <text>
                        <paragraph>Serious cardiopulmonary reactions including fatalities have occurred uncommonly during or shortly following perflutren-containing microsphere administration, typically within 30 minutes of administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).</paragraph>
                        <paragraph>The reported reactions to perflutren-containing microspheres include: fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness and convulsions <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Always have cardiopulmonary resuscitation personnel and equipment readily available prior to OPTISON administration and monitor all patients for acute reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="60fd91a6-730d-4cf2-9fb0-324804756045"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Serious anaphylactic reactions have been observed during or shortly following perflutren-containing microsphere administration including: shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema have occurred in patients with no prior exposure to perflutren-containing microsphere products. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to OPTISON administration and monitor all patients for hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="97c6c909-7986-4246-9c5c-e5b723bb57fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Systemic Embolization</title>
                     <text>
                        <paragraph>When administering OPTISON to patients with a cardiac shunt, microspheres can bypass filtering of the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following OPTISON administration. OPTISON is only for intravenous administration; do not administer OPTISON by intra-arterial injection.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="40d8b347-1685-41ba-abd8-70803ac89a05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Ventricular Arrhythmia Related to High Mechanical Index</title>
                     <text>
                        <paragraph>High ultrasound mechanical index values may cause microsphere rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. OPTISON is not recommended for use at mechanical indices greater than 0.8.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="03026f15-3e62-4a66-bf49-1a9890eeb9ae"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Serious Cardiopulmonary Reactions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Common adverse reactions (incidence ≥ 0.5%) were: headache, nausea and/or vomiting, warm sensation or flushing, dizziness, dysgeusia, chills or fever, flu-like symptoms, malaise/weakness/fatigue, chest pain, dyspnea, injection site discomfort, and erythema (<linkHtml href="#S6.1">6.1</linkHtml>). </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ca1b7634-1a14-4278-9cb5-6de2c85e6385"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1  Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="45ccd0ee-29dd-4c3d-8a3f-f855afd1284c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Adults</content>
                              </paragraph>
                              <paragraph>The safety of OPTISON was evaluated in 279 adult patients in clinical studies. These patients were 69% male, 31% female, 71% White, 19% Black or African American, 9% Hispanic or Latino, and 1% other racial or ethnic groups. Adverse reactions reported in ≥ 0.5% of patients who received OPTISON by intravenous injection are given in Table 2.</paragraph>
                              <table width="90%" ID="table2">
                                 <caption>Table 2. Adverse Reactions Reported in ≥ 0.5% of the Adult Patients who Received OPTISON in Controlled Clinical Studies </caption>
                                 <col width="55%" align="left" valign="middle"/>
                                 <col width="45%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">OPTISON <br/>n=279<br/>%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Body as a Whole</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Headache</td>
                                       <td styleCode="Rrule">5.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Warm Sensation/Flushing</td>
                                       <td styleCode="Rrule">3.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Chills/fever</td>
                                       <td styleCode="Rrule">1.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Flu-like Symptoms</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Malaise/Weakness/Fatigue</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cardiovascular System</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Dizziness</td>
                                       <td styleCode="Rrule">2.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Chest Pain</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Digestive System</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Nausea and/or Vomiting</td>
                                       <td styleCode="Rrule">4.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Respiratory System</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Dyspnea</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Skin &amp; Appendages</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Injection Site Discomfort</td>
                                       <td styleCode="Rrule">1.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Erythema</td>
                                       <td styleCode="Rrule">0.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Special Senses</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Dysgeusia</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Adverse reactions reported in &lt; 0.5% of patients who received OPTISON included:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Body as a Whole:</content> induration, discoloration at the injection site <br/>
                                 <content styleCode="italics">Cardiovascular system</content>: premature ventricular contractions, palpitations<br/>
                                 <content styleCode="italics">Digestive system</content>: dry mouth<br/>
                                 <content styleCode="italics">Immune system disorders</content>: hypersensitivity <br/>
                                 <content styleCode="italics">Musculoskeletal and connective tissue disorders</content>: back pain, arthralgia, body or muscle aches<br/>
                                 <content styleCode="italics">Nervous system</content>: tremor, paresthesia, irritableness<br/>
                                 <content styleCode="italics">Respiratory system</content>: oxygen saturation decline due to coughing, wheezing<br/>
                                 <content styleCode="italics">Skin and appendages</content>: urticaria, rash, pruritus <br/>
                                 <content styleCode="italics">Special Senses</content>: tinnitus, visual blurring, photophobia, burning sensation in the eyes</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d8bc0887-2aed-40d3-8825-3e019a44011e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Pediatric Patients</content>
                              </paragraph>
                              <paragraph>Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="f63ffd56-7dc6-4c56-9e8a-cdb5b270f033"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2  Postmarketing Experience</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="ef1b46d2-8a0c-43c6-b3ae-15ecabeeef5b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions from Observational Studies</content>
                              </paragraph>
                              <paragraph>In a prospective, post-marketing safety surveillance study of OPTISON used in routine clinical practice, a total of 1,039 patients received OPTISON. These patients had an average age of 59.9 years (min, max: 20, 97) and were 62% male, 38% female, 83% White, 14% Black or African American, 2% Asian, and 1.5% other racial or ethnic groups. Overall, 17% of patients reported at least one adverse event. No deaths or serious adverse reactions were reported in this study.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="41bcee81-5abc-4330-9013-068de7ef43ba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions from Postmarking Spontaneous Reports</content>
                              </paragraph>
                              <paragraph>The following adverse reactions have been identified during the postmarketing use of OPTISON or other perflutren-containing microspheres. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                           <component>
                              <section>
                                 <id root="7df499ec-3910-476f-8435-49ed0d9b1655"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cardiopulmonary</content>
                                    </paragraph>
                                    <paragraph>Fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress or decreased oxygenation, stridor, wheezing.  </paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7770eb75-c8f7-495e-b5cd-4f056bc2b38d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Immune System</content>
                                    </paragraph>
                                    <paragraph>Anaphylaxis with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, erythema.</paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="41be1e8f-a28f-4ed3-881e-481c313e2467"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Neurologic</content>
                                    </paragraph>
                                    <paragraph>Loss of consciousness, convulsion </paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="864593f9-5b8c-40d5-8d0c-ae426ac6f871"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="S8.1">
                     <id root="5b18a6e9-d628-4f4f-bed7-6b4937763af2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="0d4c04bb-2780-4cf8-9489-7a8d6753d9d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data with OPTISON use in pregnant women to inform any drug-associated risks. No adverse developmental outcomes were observed in animal reproduction studies with  intravenous administration of OPTISON to pregnant rats and rabbits during organogenesis at doses up to at least 5 and 10 times the recommended human dose based on body surface area (<content styleCode="italics">see <linkHtml href="#DATA">Data</linkHtml>
                                 </content>).</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section ID="DATA">
                           <id root="5779aaa1-8d5f-4f94-8526-40a0ee1417c5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                           <component>
                              <section>
                                 <id root="f8c8ba57-37f3-4e9a-b8f3-6e301d1051a0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>OPTISON was administered intravenously to rats at doses of 0.25, 5 and 10 mL/kg/day (approximately 0.2, 5, and 10 times the recommended maximum human dose of 8.7 mL, respectively, based on body surface area) and to rabbits at 0.25, 2.5, and 5 mL/kg/day (approximately 0.5, 5, and 10 times the recommended maximum human dose, respectively, based on body surface area) during organogenesis. No significant findings attributable solely to a direct effect on the fetus were detected in the studies.</paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2a">
                     <id root="6c477e92-4984-4115-a0f9-7249843b2616"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2  Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of perflutren protein-type A microspheres in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for OPTISON and any potential adverse effects on the breastfed infant from OPTISON or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="0a234de8-28f7-4f67-86ab-b13566ce3b15"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of OPTISON to opacify the left ventricle and improve the delineation of the left ventricular endocardial borders have been established in pediatric patients with suboptimal echocardiograms. Use of OPTISON in pediatric patients is supported by evidence from adequate and well-controlled studies in adults and additional efficacy and safety data from a clinical study in 37 pediatric patients aged 9 to 17 years old <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>, <linkHtml href="#S14.2">14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="564fef49-5f7c-4a50-8214-d953f5414cd3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects in a clinical study of OPTISON, 35% were 65 and over, while 14% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="ccf31353-32d4-4a7d-a289-eeeef7a9bdaf"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph>OPTISON (perflutren protein-type A microspheres) injectable suspension is an ultrasound contrast agent for intravenous use. </paragraph>
                  <paragraph>Perflutren is chemically characterized as 1,1,1,2,2,3,3,3-perflutren with a molecular weight of 188, an empirical formula of C<sub>3</sub>F<sub>8</sub>, and the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Each mL contains 5-8×10<sup>8</sup> protein-type A microspheres, 10 mg albumin human, 0.22 ± 0.11 mg perflutren, and the following inactive ingredients: 0.2 mg N-acetyltryptophan and 0.12 mg caprylic acid in 0.9% aqueous sodium chloride. The headspace of the vial is filled with perflutren gas. The pH is adjusted to 6.4 to 7.4. The protein in the microsphere shell makes up approximately 5% to 7% (w/w) of the total protein in the suspension. The microsphere particle size parameters are listed in Table 3.</paragraph>
                  <paragraph>OPTISON is supplied as a clear liquid lower layer, a white liquid upper layer, and a headspace filled with perflutren gas, and after resuspension, OPTISION is a sterile, homogeneous, opaque, and milky-white suspension.</paragraph>
                  <table width="60%">
                     <caption>Table 3. Microsphere Size Distribution</caption>
                     <col width="65%" align="left" valign="top"/>
                     <col width="35%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Parameter</th>
                           <th styleCode="Rrule"/>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Mean diameter (range)</td>
                           <td styleCode="Rrule">3 to 4.5 µm</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Percent less than 10 µm</td>
                           <td styleCode="Rrule">95%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Maximum diameter</td>
                           <td styleCode="Rrule">32 µm</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="optison-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="10b22ee5-de98-4e9f-9afa-28b523cac9a7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="S12.1">
                     <id root="f9d1f816-92c6-4a2e-95c4-b77e4f8470b8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph>The OPTISON microspheres create an echogenic contrast effect in the blood. The acoustic impedance of the OPTISON microspheres is much lower than that of the blood. Therefore, impinging ultrasound waves are scattered and reflected at the microsphere-blood interface and ultimately may be visualized in the ultrasound image. At the frequencies used in adult echocardiography (2 MHz to 5 MHz), the microspheres resonate which further increases the extent of ultrasound scattering and reflection.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="eb22385f-f3e5-44da-b296-f296f1d24b33"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2  Pharmacodynamics</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="1395adb2-38e0-4e3b-b7e5-d5c3b8f5b1ef"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contrast Enhancement Duration in Adults</content>
                              </paragraph>
                              <paragraph>The median duration of OPTISON contrast enhancement for each of the four doses of OPTISON, 0.2 (40% of recommended dose), 0.5, 3, and 5 mL, were approximately one, two, four, and five minutes, respectively <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="46918346-ee8f-4927-a702-450332c51fc5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pulmonary Hemodynamic Effects</content>
                              </paragraph>
                              <paragraph>The effect of OPTISON on pulmonary hemodynamics was studied in a prospective, open-label study of 30 patients scheduled for pulmonary artery catheterization, including 19 with an elevated baseline pulmonary arterial systolic pressure (PASP) (&gt;35 mmHg) and 11 with a normal PASP (≤35 mmHg). Systemic hemodynamic parameters and ECGs were also evaluated. No clinically important pulmonary hemodynamic, systemic hemodynamic, or ECG changes were observed. </paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0b05247a-b753-48b1-80aa-c82c49763230"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph>After injection of OPTISON, diffusion of the perflutren gas out of the microspheres is limited by the low partition coefficient of the gas in blood that contributes to the persistence of the microspheres.</paragraph>
                        <paragraph>The pharmacokinetics of the intact microspheres of OPTISON in humans are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="67c97842-4958-48ae-b6e4-c57ed4e19142"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The binding of perflutren to plasma proteins and its partitioning into blood cells are unknown. However, perflutren protein binding is expected to be minimal due to the low partition coefficient of the gas in blood.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="90fe0222-eb96-449f-8a4a-d0c431ee36ac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Following  intravenous  injection, perflutren is cleared with a pulmonary elimination half-life of 1.3 ± 0.69 minutes (mean ± SD).</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                           <component>
                              <section>
                                 <id root="2f90c7ef-dd32-412a-97d5-5225683f399e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Perflutren is a stable gas that is not metabolized. The human albumin component of the microsphere is expected to be handled by the normal metabolic routes.</paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="6bd07f19-f79d-4f88-85ee-e302328caff1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Perflutren is eliminated through the lungs within 10 minutes. The mean ± SD recovery was 96% ± 23%. The perflutren concentration in expired air peaked approximately 30 to 40 seconds after administration.</paragraph>
                                 </text>
                                 <effectiveTime value="20250514"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="aa2e5925-96ae-4a4c-9b97-676beb45f930"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="S13.1">
                     <id root="48095c28-ca35-48aa-874f-209064c9f2a2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250514"/>
                     <component>
                        <section>
                           <id root="99b81ff0-4790-42e0-abd8-43968013ab72"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Animal studies were not carried out to determine the carcinogenic potential of OPTISON.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6ae65caf-d201-4cf8-8e6d-ca2c031c6ecd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>The result of the following genotoxicity studies with OPTISON were negative: 1) Salmonella/Escherichia coli reverse mutation assay, 2) <content styleCode="italics">in vitro</content> mammalian chromosome aberration assay using Chinese hamster ovary cells (CHO) with and without metabolic activation, 3) CHO/HGPRT forward mutation assay, and 4) <content styleCode="italics">in vivo</content> mammalian micronucleus assay.</paragraph>
                           </text>
                           <effectiveTime value="20250514"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="e0ead678-7387-40ea-8480-5e4796faef81"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="S14.1">
                     <id root="3ddb6fb1-37f9-4309-a075-d1a35c8a8372"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1  Echocardiography in Adults</title>
                     <text>
                        <paragraph>The effectiveness of OPTISON was evaluated in two identical multicenter, controlled, dose escalation studies in 203 adult patients (Study A: n=101, Study B: n=102) with sub-optimal non-contrast echocardiography defined as having at least two out of six segments of the left ventricular endocardial border inadequately delineated in the apical 4-chamber view. These patients were 79% male, 21% female, 64% White, 25% Black or African American, 10% Hispanic or Latino, and 1% other race or ethnic group. The patients had a mean age of 61 years (range: 21 years to 83 years), a mean weight of 196 lbs. (range: 117 lbs. to 342 lbs.), a mean height of 68 inches (range: 47 inches to 78 inches), and a mean body surface area of 2 m<sup>2</sup> (range: 1.4 m<sup>2</sup> to 2.6 m<sup>2</sup>). Approximately 23% of the patients had chronic pulmonary disease, and 17% had congestive and dilated cardiomyopathy with left ventricular ejection fractions (LVEFs) between 20% and 40% (by previous echocardiography). Patients with a LVEF of less than 20% or with New York Heart Association Class IV heart failure were not included in the studies.</paragraph>
                        <paragraph>After non-contrast imaging, OPTISON was administered in increasing increments as four doses (0.2, 0.5, 3, and 5 mL) with at least 10 minutes between each dose. Ultrasound settings were optimized for the baseline (non-contrast) apical 4-chamber view and remained unchanged for the contrast imaging. Static echocardiographic images and video-tape segments were interpreted by a reader who was blinded to the patient's clinical history and to the  dose of OPTISON. Left ventricular endocardial border delineation and left ventricular opacification were assessed before and after OPTISON administration by the measurement of visualized endocardial border length and ventricular opacification.</paragraph>
                        <paragraph>In comparison to non-contrast ultrasound, OPTISON significantly increased the length of endocardial border that could be visualized both at end-systole and end-diastole (see <linkHtml href="#TABLE4">Table 4</linkHtml>). In these patients there was a trend towards less visualization in women. OPTISON increased left ventricular opacification (peak intensity) in the mid-chamber and apical views (see <linkHtml href="#TABLE5">Table 5</linkHtml>). The imaging effects of OPTISON on endocardial border delineation and left ventricular opacification were similar at doses between 0.5 mL and 5 mL and  were also similar among patients with or without pulmonary disease and dilated cardiomyopathy.</paragraph>
                        <table width="95%" ID="TABLE4">
                           <caption>Table 4. Left Ventricular Endocardial Border Length Visualized Before and After OPTISON in Adults <footnote>The differences in the number of enrolled patients and evaluated patients at each dose reflect exclusions based on withdrawal from the trial, or those with technically inadequate or missing images.</footnote>
                              <sup>,</sup>
                              <footnote>An intent-to-treat analysis, with non-favorable values imputed for missing patients, provided qualitatively similar results.</footnote>
                           </caption>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule">Study</th>
                                 <th styleCode="Rrule" rowspan="2">OPTISON dose</th>
                                 <th styleCode="Rrule" colspan="2">Length at End-Systole (cm)</th>
                                 <th styleCode="Rrule" colspan="2">Length at End-Diastole (cm)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" align="left">Study A (n=101)</td>
                                 <td styleCode="Rrule" align="left">0 mL (baseline)</td>
                                 <td styleCode="Rrule">87</td>
                                 <td styleCode="Rrule">7.7 ± 3.0</td>
                                 <td styleCode="Rrule">86</td>
                                 <td styleCode="Rrule">9.3 ± 3.4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="left">0.5 mL</td>
                                 <td styleCode="Rrule">86</td>
                                 <td styleCode="Rrule">12.0 ± 4.9</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">15.8 ± 5.1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" align="justify">Study B (n=102)</td>
                                 <td styleCode="Rrule" align="left">0 mL (baseline)</td>
                                 <td styleCode="Rrule">89</td>
                                 <td styleCode="Rrule">8.1 ± 3.4</td>
                                 <td styleCode="Rrule">89</td>
                                 <td styleCode="Rrule">9.6 ± 3.7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule" align="left">0.5 mL</td>
                                 <td styleCode="Rrule">95</td>
                                 <td styleCode="Rrule">12.4 ± 4.9</td>
                                 <td styleCode="Rrule">97</td>
                                 <td styleCode="Rrule">16.4 ± 4.6</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="95%" ID="table5">
                           <caption>Table 5. Intensity of Left Ventricular Opacification<footnote>Intensity measured by videodensitometry in arbitrary gray scale units (0-255).</footnote> Before and After OPTISON in Adults <footnote>The differences in the number of enrolled patients and evaluated patients at each dose reflect exclusions based on withdrawal from the trial, or those with technically inadequate or missing images.</footnote>
                              <sup>,</sup>
                              <footnote>An intent-to-treat analysis, with non-favorable values imputed for missing patients, provided qualitatively similar results.</footnote>
                           </caption>
                           <col width="18%" align="left" valign="middle"/>
                           <col width="18%" align="left" valign="middle"/>
                           <col width="5%" align="left" valign="middle"/>
                           <col width="11%" align="left" valign="middle"/>
                           <col width="5%" align="left" valign="middle"/>
                           <col width="11%" align="left" valign="middle"/>
                           <col width="5%" align="left" valign="middle"/>
                           <col width="11%" align="left" valign="middle"/>
                           <col width="5%" align="left" valign="middle"/>
                           <col width="11%" align="left" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" align="center">Study</th>
                                 <th styleCode="Rrule" rowspan="3" align="center">OPTISON dose</th>
                                 <th styleCode="Rrule" colspan="4" align="center">Mid-Chamber</th>
                                 <th styleCode="Rrule" colspan="4" align="center">Apex</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" colspan="2">Intensity at End-Diastole</th>
                                 <th styleCode="Rrule" colspan="2">Intensity at End-Systole</th>
                                 <th styleCode="Rrule" colspan="2">Intensity at End-Diastole</th>
                                 <th styleCode="Rrule" colspan="2">Intensity at End-Systole</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                                 <th styleCode="Rrule">n</th>
                                 <th styleCode="Rrule">mean ± S.D.</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Study A (n=101)</td>
                                 <td styleCode="Rrule">0 mL (baseline)</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">39.5 ± 16.9</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">40.0 ± 18.1</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">46.7 ± 19.7</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">46.9 ± 20.1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">0.5 mL</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">57.3 ± 26.8</td>
                                 <td styleCode="Rrule">90</td>
                                 <td styleCode="Rrule">57.4 ± 26.7</td>
                                 <td styleCode="Rrule">91</td>
                                 <td styleCode="Rrule">67.0 ± 30.1</td>
                                 <td styleCode="Rrule">90</td>
                                 <td styleCode="Rrule">64.1 ± 30.2</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Study B (n=102)</td>
                                 <td styleCode="Rrule">0 mL (baseline)</td>
                                 <td styleCode="Rrule">95</td>
                                 <td styleCode="Rrule">40.4 ± 17.4</td>
                                 <td styleCode="Rrule">95</td>
                                 <td styleCode="Rrule">40.9 ± 17.5</td>
                                 <td styleCode="Rrule">95</td>
                                 <td styleCode="Rrule">43.7 ± 19.9</td>
                                 <td styleCode="Rrule">95</td>
                                 <td styleCode="Rrule">45.0 ± 19.6</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">0.5 mL</td>
                                 <td styleCode="Rrule">97</td>
                                 <td styleCode="Rrule">53.3 ± 20.7</td>
                                 <td styleCode="Rrule">96</td>
                                 <td styleCode="Rrule">53.6 ± 21.0</td>
                                 <td styleCode="Rrule">97</td>
                                 <td styleCode="Rrule">64.4 ± 25.3</td>
                                 <td styleCode="Rrule">96</td>
                                 <td styleCode="Rrule">61.6 ± 26.7</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="8a7976c2-45ff-42e4-a401-d85c56be5ed5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Echocardiography in Pediatric Patients</title>
                     <text>
                        <paragraph>The effectiveness of OPTISON was evaluated in a multicenter open-label clinical trial (NCT03740997) of 37 pediatric patients aged 9 to 17 years who were clinically indicated for transthoracic echocardiography and had suboptimal non-contrast echocardiography, defined as at least two contiguous segments in any view that could not be visualized. </paragraph>
                        <paragraph>These patients were 62% male, 38% female, 70% White, 8% Black or African American, 3% Asian, 3% American Indian or Alaska Native, 5% multiple races, 8% unknown race, and 3% race not reported. Ethnicity distribution was 49% Hispanic or Latino, 47% not Hispanic or Latino, and 3% not reported. </paragraph>
                        <paragraph>After non-contrast echocardiography, two increasing doses of OPTISON (dose level 1 and 2) based on body weight were administered with at least 10 minutes between doses. Contrast and non-contrast images for each patient were evaluated by three independent readers who were blinded to clinical information. Readers assessed visualization of 12 segments of the left ventricular wall in standard apical 4- and 2-chamber views on a 4-point Endocardial Border Delineation scale (0 to 3, indicating no, poor, fair, and good/optimal visualization). Segments scored 2 or 3 were considered visualized. The mean number of visualized segments of left ventricular wall under non-contrast echocardiography, echocardiography following OPTISON at dose level 2 (0.2 mL, 0.3 mL, or 0.4 mL, depending on body weight), and the difference (OPTISON at dose level 2 minus non-contrast) for the 37 patients in the full analysis set are shown in Table 6.</paragraph>
                        <table width="80%" ID="table6">
                           <caption>Table 6. Mean Number of Left Ventricular Wall Segments Visualized by Reader in Pediatric Patients (n=37 patients)<footnote>The full analysis set population consists of all 37 enrolled patients who had echocardiographic images collected both before and after OPTISON administration, irrespective of the quality of the OPTISON images. The number of segments visualized was based on the Endocardial Border Delineation score (segments rated as "2 = fair visualization" or "3 = good/optimal visualization") and ranged from 0 to 12.</footnote>
                           </caption>
                           <col width="15%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="35%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Reader</th>
                                 <th styleCode="Rrule">Non-Contrast <br/>Mean (SD)</th>
                                 <th styleCode="Rrule">OPTISON Dose Level<br/> 2<footnote>Dose level 2 was 0.2 mL, 0.3 mL, or 0.4 mL, depending on body weight </footnote>
                                    <br/>Mean (SD)</th>
                                 <th styleCode="Rrule">Difference Between OPTISON<br/> Dose Level 2 &amp; Non-Contrast<br/> Mean (95% CI)<footnote>CI=Confidence Interval </footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Reader 1 </td>
                                 <td styleCode="Rrule">3.3 (3.4)</td>
                                 <td styleCode="Rrule">9.2 (4.3)</td>
                                 <td styleCode="Rrule">5.9 (4.4, 7.5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Reader 2</td>
                                 <td styleCode="Rrule">2.8 (2.8)</td>
                                 <td styleCode="Rrule">9.0 (4.7)</td>
                                 <td styleCode="Rrule">6.2 (4.4, 8.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Reader 3</td>
                                 <td styleCode="Rrule">4.6 (5.0)</td>
                                 <td styleCode="Rrule">9.3 (4.1)</td>
                                 <td styleCode="Rrule">4.6 (2.6, 6.7)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="06488fe8-afb1-4549-88ae-5bd57d856960"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="S16.1">
                     <id root="6bd2c084-2117-4cc0-87ed-c77e71b9a60d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>OPTISON (perflutren protein-type A microspheres) injectable suspension is supplied  at concentrations of 5-8×10<sup>8</sup>/mL protein-type A microspheres, 10 mg/mL albumin human, and 0.22 ± 0.11 mg/mL perflutren as a clear liquid lower layer, a white liquid upper layer, and a headspace filled with perflutren gas in 3 mL single-patient use vials. After resuspension, OPTISON is a sterile, homogeneous, opaque, and milky-white injectable suspension.</paragraph>
                        <table width="60%" styleCode="Noautorules">
                           <col align="left" valign="top" width="60%"/>
                           <col align="left" valign="top" width="40%"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Five (5) – 3 mL vials per carton</item>
                                       <item>Eighteen (18) – 3 mL vials per carton</item>
                                    </list>
                                 </td>
                                 <td>NDC 0407-2707-03<br/> NDC 0407-2707-18</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="906e1742-c539-49d4-ace2-e5fdb1f813b8"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Upon receipt, store OPTISON refrigerated between 2°C to 8°C (36°F to 46°F). Storage at room temperature (up to 25°C or 77°F) for up to 24 hours is permitted. Do not freeze.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ef04339a-4053-4a38-abcf-a07fc37a5307"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250514"/>
               <component>
                  <section>
                     <id root="09cab3a0-c91e-4291-ba3f-38d63ed4c66b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider if they develop any symptoms of hypersensitivity after OPTISON administration including rash, wheezing, or shortness of breath <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="633ad371-a563-43ba-983e-c176d04169f3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by <br/>GE Healthcare Inc. <br/>Arlington Heights, IL 60004</paragraph>
                  <paragraph>OPTISON™ is a trademark of GE HealthCare or one of its subsidiaries. <br/>GE is a trademark of General Electric Company used under trademark license.</paragraph>
                  <paragraph>© 2025 GE HealthCare</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="25bdf9b8-c873-4039-9971-134b24e8da40"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3 mL Vial Carton Label</title>
               <text>
                  <paragraph>GE Healthcare<br/>NDC 0407-2707-18<br/>Rx ONLY</paragraph>
                  <paragraph>OPTISON™<br/>(Perflutren Protein-Type A<br/>Microspheres Injectable<br/>Suspension, USP)<br/>3 mL</paragraph>
                  <paragraph>2707-18<br/>Contains<br/>18 x 3 mL Vials</paragraph>
                  <paragraph>(01)20304072707183</paragraph>
                  <paragraph>EXP.: DD MMM YYYY<br/>LOT: 12345678</paragraph>
                  <paragraph>1200602 USA</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 3 mL Vial Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="optison-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>